Skip to main navigation
OricPharma logo
About
Overview
Leadership Team
Board of Directors
Founders
Contact
Pipeline
Overview
Rinzimetostat
Enozertinib
Publications
Patients
Overview
Clinical Trials
Investors & News
Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
Corporate Governance
SEC Filings
Quarterly Results
Investor FAQs
Contact IR
Careers
Overview
Culture & Values
Benefits
Current Openings
CONTACT US
info@oricpharma.com
(650) 388-5600
Event Details
Rinzimetostat (ORIC-944) Program Update Call
Mar 31, 2026 at 4:30 PM EDT
Webcast
PRINT
EMAIL PAGE
Contact IR
RSS
Email Alerts
OricPharma logo
